Q4 2025 Aptargroup Inc Earnings Call Transcript
Key Points
- AptarGroup Inc (ATR) reported a strong top-line performance with a 14% increase in reported sales for Q4 2025, reaching $963 million.
- Core sales increased by 5%, indicating healthy underlying demand across the company's portfolio.
- The Pharma segment showed significant growth, with core sales excluding emergency medicine increasing by 10% in Q4.
- The Beauty segment delivered double-digit core sales growth, driven by strong demand in fragrance, facial skincare, and personal care.
- AptarGroup Inc (ATR) returned $486 million to shareholders in 2025 through share repurchases and dividends, marking its 32nd consecutive year of increasing dividends.
- Adjusted EBITDA margin decreased to 19.8% from 23% in the prior year, impacted by less favorable product mix and higher production costs in Beauty and Closures segments.
- The Beauty segment faced operational disruptions, including environmental upgrades and supplier issues, affecting margins.
- The Closures segment experienced a decline in adjusted EBITDA margin due to equipment maintenance issues and lower resin pricing.
- Emergency medicine sales declined by 36%, creating a significant headwind for the Pharma segment.
- Adjusted earnings per share decreased by 23% year-over-year, impacted by higher depreciation, amortization expenses, and interest expenses.
Ladies and gentlemen, thank you for standing by. Welcome to Aptar's 2025 fourth-quarter and annual results conference call. (Operator Instructions)
Introducing today's conference call is Ms. Mary Skafidas, Senior Vice President, Investor Relations and Communications. Please go ahead.
Thank you. Hello, everyone, and thanks for being with us today. Our speakers for the call are Stephan Tanda, our President and CEO; and Vanessa Kanu, our Executive Vice President and CFO.
Our press release and accompanying slide deck have been posted on our website under the Investor Relations page. During this call, we will be discussing certain non-GAAP financial measures. These measures are reconciled to the most directly comparable GAAP financial measure and the reconciliations are set forth in the press release. Please refer to the press release disseminated yesterday for reconciliations of non-GAAP measures to the most comparable GAAP measures discussed during this earnings call. As always, we will also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
